Henovcom

Guangzhou Henovcom Bioscience Co., Ltd., founded in 2013 in Guangzhou, China by biopharmaceutical veterans from Gilead, Pfizer, and Novartis, is dedicated to the discovery, development, and commercialization of innovative therapies targeting unmet medical needs in areas such as antiviral, anti-fibrotic, inflammatory, and central nervous system (CNS) diseases. The company currently has four novel molecular entities (NMEs) in clinical development across the U.S. and China and holds over 70 global patent filings.

Henovcom features a highly skilled R&D team and integrated drug discovery and development platforms encompassing medicinal chemistry, API process development, and clinical operations.

With deep expertise in nucleoside modifications and nucleic acid chemistry, Henovcom has developed the proprietary mRNA capping agent LZCap® and safe, effective ionizable lipids both for research and GMP-grade commercial scale. These innovations significantly enhance the cost-efficiency and safety of Henovcom’s pipeline in protein replacement therapies and therapeutic vaccines with high and repeat dosing regimen.